Schizophrenia
- Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug (PubMed)
- Cannabidiol as a potential treatment for psychosis (PubMed)
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia(PubMed)
- Medical use of cannabis. Cannabidiol: A new light for schizophrenia? (PubMed)
- A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation(PubMed)
- Peripheral endocannabinoid system dysregulation in first-episode psychosis (PubMed)
- Cannabinoids and schizophrenia: Therapeutic prospects (PubMed)
- Antipsychotic-like effects of cannabidiol and rimonabant: Systematic review of animal and human studies (PubMed)
- Cannabidiol monotherapy for treatment-resistant schizophrenia (PubMed)
- Cannabis with high cannabidiol content is associated with fewer psychotic experiences (PubMed)
- Marijuana compound treats schizophrenia with few side effects: Clinical trial (Time)
- Clearing the smoke: what do we know about adolescent cannabis use and schizophrenia?(PubMed)
- Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis (The British Journal of Psychiatry)
- Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain (Frontiers and Pharmacology)
- A clinical comparison of schizophrenia with and without pre-onset cannabis use disorder: a retrospective cohort study using categorical and dimensional approaches (Annals of General Psychiatry)
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia (Macmillan Publishers Limited)
- Cannabidiol Reverses MK-801-Induced Disruption of Prepulse Inhibition in Mice (Neuropsychopharmacology)